Calcium phosphate kidney stones account for a meaningful and growing share of all kidney stones, and they present treatment challenges that calcium oxalate stones, the most common type, do not. While calcium oxalate makes up the majority of stones, calcium phosphate can appear as the dominant mineral in a stone or as a significant component mixed with oxalate. The share of stones containing substantial calcium phosphate has been climbing for decades, and these stones tend to signal specific urinary chemistry problems that require targeted workup and management.
Apatite and Brushite Are Not the Same Stone
Calcium phosphate kidney stones come in two main mineral forms, and the distinction matters clinically. Apatite (also called hydroxyapatite) is the more common variety. It tends to form in urine with a pH above about 6.5 and often grows as a mix of tiny particles embedded in organic material. Brushite is less common and forms in more acidic conditions than apatite, though still at a higher pH than typical calcium oxalate stones. Brushite stones are denser, harder, and more crystalline in structure.
The physical differences between the two translate into different clinical behavior. Apatite stones contain more protein and more internal void space than brushite stones. One study found that apatite stones averaged roughly 11% void volume and 6% protein content, compared to about 3% void volume and 4% protein for brushite.
Brushite stones are the more stubborn of the two. They resist shock wave lithotripsy and ultrasonic fragmentation, often requiring ballistic or laser energy to break apart. Patients with brushite stones are less likely to be rendered completely stone-free after surgery and tend to experience recurrence even with aggressive medical management.1PubMed Central. Brushite stone disease as a consequence of lithotripsy? The urinary chemistry profile also differs: brushite stone formers have been found to excrete substantially more calcium in their urine than apatite stone formers, with mean 24-hour calcium of roughly 330 mg versus 205 mg.2PubMed. Differences in 24-hour urine composition between apatite and brushite stone formers
What Makes Calcium Phosphate Crystallize in Your Kidneys
The single biggest driver of calcium phosphate stone formation is alkaline urine. When urinary pH rises above about 6.5, the saturation of calcium phosphate increases sharply. Calcium oxalate, by contrast, is less sensitive to pH shifts. So the same urine that might not form a calcium oxalate stone could easily become supersaturated with calcium phosphate if the pH tips upward.
The second major factor is low urinary citrate. Citrate acts as a natural brake on stone formation by binding calcium in the urine, preventing it from linking up with phosphate or oxalate. It also directly blocks the growth and clumping of crystals.3PubMed Central. Hypocitraturia: pathophysiology and medical management When citrate drops, calcium is freed up to combine with phosphate, and the crystallization process faces fewer obstacles.
High urinary calcium, the third piece of the puzzle, can stem from diet, hormonal conditions, or inherited traits. When all three factors converge in the same person, the risk of calcium phosphate stones is especially high. This combination of alkaline pH, low citrate, and high calcium is what clinicians look for when a patient passes a calcium phosphate stone.
Conditions That Push Urine Toward Calcium Phosphate Stones
Calcium phosphate stones are not just a random occurrence. They frequently signal an underlying condition that is shifting urinary chemistry in a specific direction. Three conditions deserve particular attention.
Distal Renal Tubular Acidosis
Distal renal tubular acidosis, or dRTA, is probably the most well-known driver of calcium phosphate stones. In dRTA, the kidney’s distal tubule cannot properly excrete acid into the urine, which keeps urinary pH persistently high and citrate levels low. That combination is tailor-made for calcium phosphate precipitation.4PubMed. Renal tubular acidosis (RTA) and kidney stones: Diagnosis and management Anyone found to have a calcium phosphate stone with low citrate and a consistently elevated urine pH, especially a morning pH above 5.5, should be evaluated for dRTA.
The link between dRTA and calcium phosphate stones goes beyond chemistry. Kidney biopsies from dRTA patients who form stones show plugging of the inner medullary collecting ducts and Bellini ducts with apatite deposits, along with significant damage to the cells lining those ducts.5PubMed. Renal histopathology of stone-forming patients with distal renal tubular acidosis In other words, the alkaline environment does not just create stones floating in urine; it causes mineral deposits to form directly inside the kidney tissue itself.
Among patients who form calcium phosphate stones, the rate of underlying dRTA is surprisingly high. One study using a furosemide challenge test found that about 35% of calcium phosphate stone formers had dRTA.6PubMed. Prevalence of distal renal tubular acidosis in patients with calcium phosphate stones The condition can also be spotted by stone morphology: a distinctive smooth, glazed brown-yellow appearance with tiny surface cracks (termed IVa2 morphology) was found in over 96% of stones associated with inherited dRTA.7PubMed. Calcium phosphate stone morphology can reliably predict distal renal tubular acidosis The same morphology appeared in a majority of calcium phosphate stones from patients with Sjögren syndrome and in about a third of those from patients with medullary sponge kidney, both conditions associated with milder acidification defects.
Primary Hyperparathyroidism
Primary hyperparathyroidism, where one or more parathyroid glands overproduce parathyroid hormone, is another well-established cause. The excess hormone drives calcium out of bone and into the bloodstream and then into the urine, creating hypercalciuria. At the same time, parathyroid hormone affects how the kidney handles bicarbonate and phosphate, which can push urine pH upward. The combination of high urinary calcium and alkaline urine makes calcium phosphate stones a recognized risk in this condition.8The Journal of Clinical Endocrinology & Metabolism. Nephrolithiasis and Renal Calcifications in Primary Hyperparathyroidism
Medications That Alter Urine Chemistry
Certain drugs can create the urinary environment needed for calcium phosphate stones. Topiramate, used for epilepsy and migraines, is a well-known offender. It can cause a type of metabolic acidosis by inhibiting carbonic anhydrase in the kidney, paradoxically leading to alkaline urine despite the blood being acidic. A case study documented a topiramate-treated patient with markedly low bicarbonate, alkaline urine pH of 6.39, and a severely depressed urine citrate of just 0.3 mmol per 24 hours, creating ideal conditions for calcium phosphate stone formation.9PubMed Central. Topiramate induced metabolic acidosis and kidney stones – a case study Carbonic anhydrase inhibitors used for glaucoma can have a similar effect.
How Dietary Sodium Feeds the Problem
Sodium intake has a direct and surprisingly powerful effect on the urinary factors that drive calcium phosphate stones. When healthy subjects were placed on a high-sodium diet, their urinary calcium jumped from about 2.7 to 3.9 mmol per day, urinary pH rose from 5.79 to 6.15, and citrate fell from 3.14 to 2.52 mmol per day.10PubMed. The potential role of salt abuse on the risk for kidney stone formation High sodium essentially hits every one of the three risk factors at once: more calcium in the urine, higher pH, and less citrate to inhibit crystallization. The resulting change in urine saturation was confirmed directly, with calcium phosphate (brushite) supersaturation increasing measurably.
This makes sodium restriction one of the more straightforward dietary interventions for calcium phosphate stone formers. Reducing sodium intake lowers urinary calcium excretion, which is expected to reduce recurrence.11PubMed. Optimum nutrition for kidney stone disease The typical recommendation is to keep sodium under 2,300 mg per day, and ideally closer to 1,500 mg for recurrent stone formers. Most people eating a standard Western diet are well above these targets.
The Citrate Paradox in Treatment
Here is where managing calcium phosphate stones gets genuinely tricky, and where these stones diverge most sharply from calcium oxalate in terms of treatment strategy. Potassium citrate is one of the most commonly prescribed medications for kidney stone prevention. It raises urinary citrate, which inhibits crystallization, and it can also lower urinary calcium by improving how the kidney handles calcium. For calcium oxalate stone formers, it works well.
For calcium phosphate stone formers, potassium citrate is a double-edged sword. The medication raises urinary citrate (beneficial), but it also raises urinary pH (potentially harmful). Because calcium phosphate crystallization is so sensitive to pH, the pH increase can push saturation higher and partially cancel out the benefit of the added citrate.12Clinical Kidney Journal. Citrate and calcium kidney stones Calcium phosphate stone disease has been called one of the biggest treatment challenges in kidney stone medicine for exactly this reason.
Study data on the actual effect are mixed and somewhat limited. One analysis found that potassium citrate consistently raised urine pH in both calcium oxalate and calcium phosphate stone formers. Among calcium oxalate formers who received citrate alone, calcium phosphate supersaturation actually increased. Among calcium phosphate formers, the supersaturation did not change significantly with citrate alone, though the researchers noted that this finding was limited by a small sample size.13PubMed Central. Contrasting Response of Urine Stone Risk to Medical Treatment in Calcium Oxalate versus Calcium Phosphate Stone Formers
In practice, clinicians often pair potassium citrate with a thiazide diuretic. Thiazides lower urinary calcium excretion, which can help offset the pH-related increase in calcium phosphate saturation that citrate causes. High fluid intake to increase urine volume and sodium restriction round out the standard approach.14Clinical Journal of the American Society of Nephrology. A Woman with Recurrent Calcium Phosphate Kidney Stones No randomized clinical trials have specifically tested any of these strategies for calcium phosphate stone prevention, so treatment recommendations are largely extrapolated from calcium oxalate trial data and from understanding of urinary chemistry.
Surgical Treatment Is More Difficult
Calcium phosphate composition affects more than just medical management. When stones need to be removed, calcium phosphate content makes the procedure harder. One study comparing ureteroscopic laser lithotripsy outcomes found that patients with calcium phosphate stones needed significantly longer operation times and more laser energy than those with pure calcium oxalate stones, and they had a significantly higher stone clearance rate issue (meaning more residual fragments remained after the procedure).15PubMed Central. Brushite stone disease as a consequence of lithotripsy? Brushite stones are the worst offenders here, as noted earlier, but even apatite-dominant stones can be harder to fragment than pure calcium oxalate.
There is also a controversial hypothesis that shock wave lithotripsy itself can shift stone chemistry toward calcium phosphate in recurrent formers. The theory is that tissue injury from shock waves damages kidney cells in a way that promotes subsequent calcium phosphate deposition, potentially converting what was originally a calcium oxalate problem into a calcium phosphate one. The evidence for this remains debated, but it has made some urologists more cautious about repeated shock wave treatment in patients whose stones already contain phosphate.
Calcium Phosphate as a Seed for Calcium Oxalate Stones
One of the more interesting aspects of calcium phosphate in stone disease is that it plays a role even in stones that are predominantly calcium oxalate. Research has shown that amorphous calcium phosphate particles can act as nucleation sites for calcium oxalate crystallization. Laboratory experiments demonstrated that small calcium oxalate clusters, just a few nanometers across, aggregate on the surface of larger amorphous calcium phosphate spheres, and these coaggregates eventually serve as the seed for further stone growth.16PubMed Central. Aggregation of Calcium Phosphate and Oxalate Phases in the Formation of Renal Stones
This process is not limited to Randall’s plaques, the small calcium phosphate deposits in kidney tissue that have long been recognized as starting points for calcium oxalate stones. A more recent study found that dispersed calcium phosphate microcrystals in various forms, not just established plaques, can promote the growth of concentric calcium oxalate monohydrate structures. The researchers suggested that patients whose urine contains higher quantities of calcium phosphate crystals may be more prone to forming hard, troublesome calcium oxalate stones, even if their stones are not classified as calcium phosphate-dominant.17Biomedical Research. Calcium phosphate controls nucleation and growth of calcium oxalate crystal phases in kidney stones
This seeding role means that the clinical significance of calcium phosphate extends well beyond the subset of patients who form predominantly phosphate stones. It suggests that managing urinary phosphate saturation could benefit a broader group of stone formers than traditionally thought.
Why Predicting Stone Type From Urine Tests Alone Is Unreliable
You might expect that a 24-hour urine collection, the standard metabolic workup for stone formers, would reliably distinguish calcium phosphate stones from calcium oxalate or uric acid stones. It does not. One study that built a statistical model to predict stone type from 24-hour urine composition correctly identified calcium phosphate stones in only 31% of actual cases, and of the stones it predicted as calcium phosphate, only 56% actually were.18PubMed. Using 24-hour urinalysis to predict stone type The overall accuracy of urine-based prediction across all stone types was just 64%.
This is why actual stone analysis is considered essential. Whenever you pass a stone or have one surgically removed, catching it and sending it for compositional analysis tells you and your doctor far more than urine chemistry alone. Stone composition directs the workup: a stone that is predominantly calcium phosphate should trigger an evaluation for dRTA and hyperparathyroidism, while a stone that is mostly calcium oxalate with a calcium phosphate core points toward Randall’s plaque-mediated formation. The treatment implications differ in each case.
Long-Term Kidney Health and Rising Prevalence
Calcium phosphate stones are associated with a greater risk to kidney function over time compared to calcium oxalate stones. The tissue inflammation linked to calcium phosphate deposits can lead to scarring and chronic kidney disease.19Kidney Medicine. Calcium Phosphate Nephrolithiasis: A Comprehensive Review This is partly because of the duct-plugging mechanism seen in conditions like dRTA, where mineral deposits form inside the kidney tissue itself rather than simply growing in the open spaces where urine collects. That direct tissue injury, with destruction of the cells lining the collecting ducts, is more damaging than a stone sitting in the renal pelvis.
The prevalence of calcium phosphate stones has been rising for at least three decades, with the increase especially pronounced among women.20PubMed. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones The reasons are not entirely clear, but several hypotheses exist. Wider use of potassium citrate and other alkalinizing therapies may be shifting urine pH upward in treated stone formers, inadvertently favoring calcium phosphate over calcium oxalate. Changes in diet, increasing rates of obesity and metabolic syndrome, and the growing use of medications like topiramate could also play a role. Whatever the cause, the trend means that clinicians and patients alike need to be more aware of calcium phosphate as a distinct entity with its own management challenges, rather than lumping all calcium stones into a single treatment category.
Connections to Cardiovascular Disease
An emerging area of research links kidney stone composition to broader metabolic health. Stone formers with cardiovascular disease have been found to have lower urinary citrate and magnesium, lower 24-hour urine pH, and a higher prevalence of hypocitraturia compared to stone formers without heart disease.21PubMed Central. Urinary metabolic profile and stone composition in kidney stone formers with and without heart disease While the lower pH in this group might seem to favor calcium oxalate over calcium phosphate, the low citrate is a shared risk factor for both stone types. The broader point is that kidney stone chemistry does not exist in isolation from the rest of your health. Metabolic patterns that promote stone formation, including those that drive calcium phosphate stones, overlap with patterns that increase cardiovascular risk. This is an active area of investigation, and it reinforces why a thorough metabolic evaluation matters when you are forming calcium-based stones of any type.